The Prevalence of Epilepsy in the Nakhichevan Autonomous Republic of Azerbaijan
Abstract:Epilepsy is a devastating neurological disorder in which those afflicted can gain benefit from specific treatments based on their genetics and geographic location. Currently the prevalence of epilepsy is estimated at 0.5-3% of the world-wide population, and is increasing in developing countries. In order to make more accurate assessments of the prevalence of epilepsy, we applied the capture-recapture method in a 12-month study of epilepsy in a population from the Sharur district of Nakhichevan Autonomous Republic, Azerbaijan with 114,451 people from sixty nine villages and towns. The following methods were applied to determine epilepsy: Door To Door (DTD) survey, Non-Medical Source (NMS), and Medical Source. Using these three techniques, 1,032 patients with epilepsy (9.02/1000) were included in our study. The DTD survey determined 627 patients with epilepsy (5.48/1000) and 247 (2.16/1000) from the NMS methods versus 158 (1.38/1000) from the Medical Source (MS) methods. Applying the capture-recapture method, NMS, and DTD methods, the number of epilepsy cases increased to 1,330 (11.62/1000) [95% CI: 10.21-13.03]. The combinations of these methods show that 887 people (7.75/1000) have a diagnosis of epilepsy. Multiple epidemiological tasks used in our study can be used to estimate clinical signs and/or markers in future applications for the determination and development of treatment strategies for this devastating disease in the third world countries such as the Nakhichevan Autonomous Republic of Azerbaijan.
Keywords: ADHD; Azerbaijan; Epilepsy; MTA-SNAP-IV; Migraine; Population Study; attention-deficit hyperactivity disorder; autism spectrum disorder; door-to-door; hysteria; medical sources; non medical sources
Document Type: Research Article
Affiliations: School of Health Science and Healthcare Administration, University of Atlanta, 6685 Peachtree Industrial Blvd, Atlanta, GA 30360, USA.
Publication date: March 1, 2012
- CNS & Neurological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in neurological and central nervous system (CNS) disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will contain a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in neurological and CNS disorders. As the discovery, identification, characterization and validation of novel human drug targets for neurological and CNS drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.